Provided by Tiger Trade Technology Pte. Ltd.

Rocket Pharmaceuticals, Inc.

3.16
+0.16005.33%
Post-market: 3.190.0346+1.09%19:31 EST
Volume:2.18M
Turnover:6.91M
Market Cap:341.98M
PE:-1.41
High:3.22
Open:3.10
Low:3.07
Close:3.00
52wk High:11.11
52wk Low:2.19
Shares:108.22M
Float Shares:78.79M
Volume Ratio:1.15
T/O Rate:2.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.2397
EPS(LYR):-2.7292
ROE:-74.88%
ROA:-40.56%
PB:1.09
PE(LYR):-1.16

Loading ...

Rocket Pharmaceuticals Director Elisabeth Bjork Acquires Common Shares

Reuters
·
Jan 07

Rocket Pharmaceuticals to Present at J.P. Morgan Healthcare Conference

Reuters
·
Jan 05

Rocket Pharmaceuticals Seen With Continued Progress in 2026 -- Market Talk

Dow Jones
·
Jan 03

Rocket Pharmaceuticals CEO to Join Evercore Healthcare Conference Fireside Chat

Reuters
·
Nov 25, 2025

Rocket Pharmaceuticals CEO Gaurav Shah Reports Sale of Common Shares

Reuters
·
Nov 21, 2025

Rocket Pharmaceuticals Shares Lower After JPMorgan Downgrade

MT Newswires Live
·
Nov 19, 2025

Rocket Pharmaceuticals Is Maintained at Buy by B of A Securities

Dow Jones
·
Nov 19, 2025

JPMorgan Downgrades Rocket Pharmaceuticals to Underweight From Neutral

MT Newswires Live
·
Nov 18, 2025

Rocket Pharmaceuticals (RCKT) Receives a Buy from Bank of America Securities

TIPRANKS
·
Nov 18, 2025

Rocket Pharmaceuticals Inc : JP Morgan Cuts to Underweight From Neutral

THOMSON REUTERS
·
Nov 18, 2025

Cantor Fitzgerald Sticks to Its Buy Rating for Rocket Pharmaceuticals (RCKT)

TIPRANKS
·
Nov 07, 2025

Rocket Pharmaceuticals Q3 EPS $(0.45) Beats $(0.52) Estimate

Benzinga
·
Nov 07, 2025

Rocket Pharmaceuticals Q3 net loss narrows

Reuters
·
Nov 07, 2025

Rocket Pharmaceuticals Q3 Net Income USD -50.3 Million

THOMSON REUTERS
·
Nov 07, 2025

Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress

THOMSON REUTERS
·
Nov 07, 2025

FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy

Benzinga_recent_news
·
Nov 05, 2025

Rocket Pharmaceuticals Inc expected to post a loss of 50 cents a share - Earnings Preview

Reuters
·
Nov 03, 2025

Rocket Pharmaceuticals Inc. Officer John Militello Reports Disposal of Common Shares

Reuters
·
Oct 17, 2025

Rocket Pharmaceuticals Is Maintained at Buy by Chardan Capital

Dow Jones
·
Oct 15, 2025

Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission for KRESLADI™ Gene Therapy for Severe LAD-I; PDUFA Date Set for March 2026

Reuters
·
Oct 14, 2025